The Joint Action on Personalised Cancer Medicine (JA PCM) aims to build a cross-border network for personalised cancer medicine by uniting European countries and key stakeholders, supporting its long-term uptake across Europe. Through three coordinated arms and multiple concrete pilot actions, the initiative focuses on advancing personalised cancer care along the entire patient pathway from prevention and early detection to diagnosis, treatment, and (follow-up) tertiary prevention.

    More    

JA PCM ARMS